New heart device aims to zap away irregular rhythm

NCT ID NCT05501873

Ongoing Disease control Sponsor: Boston Scientific Corporation Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 24, 2026 · Updated 2 times

Summary

This study is tracking over 1,100 people with atrial fibrillation who are treated with the FARAPULSE system, a device that uses electrical pulses to destroy tiny areas of heart tissue causing the irregular rhythm. The goal is to see how well it works and how safe it is in everyday hospital use. Researchers will check if patients stay in normal rhythm for at least 12 months after the procedure.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: FARAPULSE Pulsed Field Ablation system (a device that uses electrical pulses to destroy abnormal heart tissue)
What this could lead to: If successful, this could confirm that pulsed field ablation is a safe and effective way to treat atrial fibrillation and restore normal heart rhythm.
What could go wrong: This is an observational registry, not a controlled trial, so results may be less definitive. Risks include device- or procedure-related serious side effects, and long-term benefits are still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atrial fibrillation

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ATRIAL FIBRILLATION

Contacts and locations

Locations

AZ Sint Jan Hospital

Bruges, Belgium
Allgemeines Krankenhaus AKH

Vienna, Austria
Az. Osp. Lancisi-Hospital

Ancona, Italy
CHR de la Citadelle

Liège, Belgium
CHU Grenoble

Grenoble, France
Casa Di Cura 'Montevergine' S.P.A.

Mercogliano, Italy
Catharina Ziekenhuis

Eindhoven, Netherlands
Centre Cardiologique du Nord

Saint-Denis, France
Centro Especial Ramon y Cajal

Madrid, Spain
Clinica Universidad de Navarra

Pamplona, Spain
Clinique Ambroise Pare-Hospital

Neuilly, France
Clinique Pasteur Toulouse

Toulouse, France
Facharztzentrum Dresden-Neustadt Betriebsgesellschaft mbH

Dresden, Germany
Fiona Stanley Hospital

Murdoch, Australia
Georg-August-Universitaet Goettingen

Göttingen, Germany
Hartcentrum Hasselt Jessa Ziekenhuis Campus Virga Jesse

Hasselt, Belgium
Henry Dunant hospital

Athens, Greece
Hopital Prive du Confluent SAS

Nantes, France
Hopital Saint Philibert-Hospital

Lomme, France
Hospital Clinico Universitario Lozano Blesa

Zaragoza, Spain
Hospital Universitario La Fe

Valencia, Spain
Hospital de Santa Cruz

Carnaxide, Portugal
Institut Jantung Negara

Kuala Lumpur, Malaysia
John Hunter Hospital

Newcastle, Australia
King Fahd Armed Forces Hospital

Jeddah, Saudi Arabia
Liverpool Heart & Chest Hospital

Liverpool, United Kingdom
Mater Private Hospital

Dublin, Ireland
Nemocnice Ceske Budejovice a.s.

České Budějovice, Czechia
Neuron Medical in Brno

Brno, Czechia
Onassis Cardiac Surgery Center

Athens, Greece
Ospedale Isola Tiberina Gemelli Isola

Roma, Italy
Ospedale Rivoli

Rivoli, Italy
Ospedale San Bortolo de Vicenza

Vicenza, Italy
Prince Charles Hospital

Brisbane, Australia
Prince of Wales Hospital

Hong Kong, Hong Kong
Princesse Grace

Monaco, Monaco
Queen Mary Hospital

Hong Kong, Hong Kong
Royal Papworth Hospital

Cambridge, United Kingdom
Semmelweis University

Budapest, Hungary
St Georg Asklepios

Hamburg, Germany
St. Antonius Ziekenhuis

Nieuwegein, Netherlands
Staedisches Klinikum Karlsruhe

Karlsruhe, Germany
Tays Heart Hospital

Tampere, Finland
Tel Aviv Sourasky Medical Center

Tel Aviv, Israel
Universitaetsklinikum Aachen (UKA)

Aachen, Germany
Universitaetsklinikum Heidelberg

Heidelberg, Germany
University Hospital of Muenster

Münster, Germany
Uniwersyteckie Centrum Kliniczne Warszawskiego Uniwersytetu Medycznego

Warsaw, Poland

More trials for these conditions

Other studies related to the condition(s) this trial covers.